Little Green Pharma Ltd (ASX: LGP) Share Price and News

Ms Fong has over 36 years in senior leadership roles in private hospitals, the public health systems, management consulting, academia, health research, aged care and not for profit organizations. Neale is currently CEO of Bethesda Health Care and formerly was Director General of the West Australian Department of Health. She is Chair of the Risk Committee.

Mr Caithness is a corporate finance executive and consultant in Australia and international markets. Following these roles, Angus acted as CFO of Erdenes Tavan Tolgoi, the owner of a coking coal deposit looking at a US$10 billion dual listing in London and Hong Kong prior to the change in the Mongolian government. Prior to that he was an Executive Director at EY in London and Australia specializing in initial public offerings of large-cap mining companies.

Mr Fenlon has over 30 years of worldwide experience in the FMCG and consumer sectors. David was previously CEO of The Platform Alliance Group. David has worked with retail brands both in Australia and offshore, with a focus on strategic planning and business transformation including in key positions with Tesco throughout Europe and Safeway in the UK. He is a Member of Risk Committee.

Ms Solomon was a founder of Little Green Pharma and grew the company from a medicinal cannabis startup to an industry leading medicinal cannabis brand in Australia and overseas. Fleta has 20 years of experience in corporate and consumer health markets.

Mr Lynch-Bell is a corporate finance executive and consultant. His early Ernst & Young career was focused on auditing clients within the oil and gas sectors and later added mining to his portfolio. He also led Ernst & Young's UK IPO and Global Natural Resources transaction teams in the Transaction Advisory practice. He has been involved advising companies on fundraising, reorganizations, transactions, corporate governance as well as IPOs. He is a former Chair of the Bureau and current member of UNECE's Expert Group on Resource Management. He is member of Risk Committee

Mr Long is an executive with over two decades of experience across the health, pharmaceutical, and medicinal cannabis industries. Paul transitioned into consultancy, advising a range of enterprise health, health tech, and retail pharmaceutical businesses. Since stepping into the role of Chief Executive Officer and now Managing Director, Paul has continued to drive strong performance and long-term growth. Paul also oversaw the doubling of revenue in Europe, supported by the expansion of LGP's Danish facility, and led the integration of the Health House acquisition.

-

-